SCHEMBL4894017

SCHEMBL4894017

Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(Cl)c2)cc1Nc1nccc(-c2cccnc2)n1

nearest known ligand 0.95

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 20/20 0.95
BCR P11274 18/20 0.95
KIT P10721 7/20 0.81
PDGFRB P09619 3/20 0.81
LYN P07948 5/20 0.71
PDGFRA P16234 3/20 0.69
SRC P12931 2/20 0.69
SYK P43405 2/20 0.69
ABL2 P42684 2/20 0.69
PLK4 O00444 1/20 0.69
DDX3X O00571 1/20 0.69
GAK O14976 1/20 0.69
SLC22A2 O15244 1/20 0.69
MAPK13 O15264 1/20 0.69
CA12 O43570 1/20 0.69
SLC22A3 O75751 1/20 0.69
ABCB11 O95342 1/20 0.69
EGFR P00533 1/20 0.69
CA1 P00915 1/20 0.69
CA2 P00918 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4890238 0.97 ABL1 (1.00) ABL1BCRKITPDGFRBLYN
SCHEMBL4891357 0.91 ABL1 (0.84) ABL1BCRKITPDGFRBLYN
SCHEMBL3557490 0.91 ABL1 (1.00) ABL1BCRKITPDGFRBLYN
SCHEMBL4882244 0.90 ABL1 (0.83) ABL1BCRKITPDGFRBLYN
SCHEMBL988910 0.90 ABL1 (0.82) ABL1BCRKITPDGFRBLYN
Flumatinib SCHEMBL30087592 0.90 ABL1 (1.00) ABL1BCRKITPDGFRBLYN
Flumatinib SCHEMBL29410819 0.90 ABL1 (1.00) ABL1BCRKITPDGFRBLYN
Flumatinib SCHEMBL29384719 0.90 ABL1 (1.00) ABL1BCRKITPDGFRBLYN
Flumatinib SCHEMBL4883843 0.90 ABL1 (1.00) ABL1BCRKITPDGFRBLYN
SCHEMBL4885468 0.89 ABL1 (0.85) ABL1BCRKITPDGFRBLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1840122-B1 AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF SUN PIAOYANG (CN) 2013-08-28 EP claimed
US-8183242-B2 Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof Sun, Piaoyang (CN) 2012-05-22 US claimed
US-20080312251-A1 Aminopyrimidine Compounds and Their Salts, Process for Preparation and Pharmaceutical Use Thereof JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2008-12-18 US claimed
EP-1840122-A1 AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF Sun, Piaoyang (CN) 2007-10-03 EP claimed
EP-1840122-B1 AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF SUN PIAOYANG (CN) 2013-08-28 EP disclosed
US-8183242-B2 Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof Sun, Piaoyang (CN) 2012-05-22 US disclosed
US-20080312251-A1 Aminopyrimidine Compounds and Their Salts, Process for Preparation and Pharmaceutical Use Thereof JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2008-12-18 US disclosed
EP-1840122-A1 AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF Sun, Piaoyang (CN) 2007-10-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312251-A1 Aminopyrimidine Compounds and Their Salts, Process for Preparation and Pharmaceutical Use Thereof DPYD, PKN2, TYMP ABL1 7/4885BCR 2529/4885KIT 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.